Daniel Basta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Basta has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Dhand
Department of Medicine, New York Medical College, Valhalla, NY
1 shared publication Assem Al Refaei
Department of Medicine, Westchester Medical Center, Valhalla, NY
1 shared publication- Bodin Roxana
Division of Gastroenterology and Hepatobiliary Diseases, Westchester Medical Center, Valhalla, NY
1 shared publication Edward Lebovics
Division of Gastroenterology & Hepatobiliary Diseases, Westchester Medical Center, Valhalla, NY
1 shared publication- Fouzia Shakil
Department of Pathology, Westchester Medical Center, Valhalla, NY
1 shared publication - Kenji Okumura
Westchester Medical Center, Department of Surgery, Valhalla, New York
1 shared publication
Latest Publications
- 13 May 2026
- Published by Wolters Kluwer Health in Cardiology in Review
Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~25–30% of adults worldwide and is increasingly recognized as a systemic cardiometabolic disorder rather than an isolated liver condition. While MASLD can progress to advanced fibrosis and cirrhosis, cardiovascular disease (CVD) is the leading cause of morbidity and mortality in this population, surpassing liver-related deaths. Beyond shared risk factors such as obesity, insulin resistance, and type 2 diabetes, MASLD is independently linked to atherosclerotic CVD, heart failure—particularly heart failure with preserved ejection fraction—and atrial arrhythmias through mechanisms including lipotoxicity, chronic inflammation, endothelial dysfunction, and atherogenic dyslipidemia. This review summarizes evidence connecting MASLD pathobiology with CVD and evaluates emerging pharmacologic strategies that target metabolic dysfunction with relevance to both hepatic and cardiovascular outcomes. We highlight 3 mechanistically complementary therapeutic classes: thyroid hormone receptor-β agonists, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter-2 inhibitors. Thyroid hormone receptor-β agonism (resmetirom) improves hepatic lipid handling, steatosis, and fibrosis while lowering apolipoprotein B-containing lipoproteins, though cardiovascular outcomes data remain pending. Glucagon-like peptide-1 receptor agonists reduce weight, improve insulin sensitivity, and lower major adverse cardiovascular events. Sodium–glucose cotransporter-2 inhibitors provide strong protection against heart failure and chronic kidney disease while improving metabolic and hepatic parameters. Together, these therapies reinforce MASLD as a cardiovascular-relevant metabolic disease and support integrated cardiometabolic approaches to reduce CVD risk.
- 13 May 2026
- Published by Wolters Kluwer Health in Cardiology in Review
Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~25–30% of adults worldwide and is increasingly recognized as a systemic cardiometabolic disorder rather than an isolated liver condition. While MASLD can progress to advanced fibrosis and cirrhosis, cardiovascular disease (CVD) is the leading cause of morbidity and mortality in this population, surpassing liver-related deaths. Beyond shared risk factors such as obesity, insulin resistance, and type 2 diabetes, MASLD is independently linked to atherosclerotic CVD, heart failure—particularly heart failure with preserved ejection fraction—and atrial arrhythmias through mechanisms including lipotoxicity, chronic inflammation, endothelial dysfunction, and atherogenic dyslipidemia. This review summarizes evidence connecting MASLD pathobiology with CVD and evaluates emerging pharmacologic strategies that target metabolic dysfunction with relevance to both hepatic and cardiovascular outcomes. We highlight 3 mechanistically complementary therapeutic classes: thyroid hormone receptor-β agonists, glucagon-like peptide-1 receptor agonists, and sodium–glucose cotransporter-2 inhibitors. Thyroid hormone receptor-β agonism (resmetirom) improves hepatic lipid handling, steatosis, and fibrosis while lowering apolipoprotein B-containing lipoproteins, though cardiovascular outcomes data remain pending. Glucagon-like peptide-1 receptor agonists reduce weight, improve insulin sensitivity, and lower major adverse cardiovascular events. Sodium–glucose cotransporter-2 inhibitors provide strong protection against heart failure and chronic kidney disease while improving metabolic and hepatic parameters. Together, these therapies reinforce MASLD as a cardiovascular-relevant metabolic disease and support integrated cardiometabolic approaches to reduce CVD risk.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (7) , e01772
Tacrolimus-Induced Acute Esophageal Necrosis Postorthotopic Liver Transplantation
Acute esophageal necrosis, or “black esophagus,” is a rare but severe condition characterized by circumferential black necrotized esophageal mucosa with an abrupt transition at the gastroesophageal junction. The “two-hit” hypothesis suggests that an initial ischemic insult predisposes the esophageal mucosa to further injury from luminal acid exposure or medications. We present the first documented case of tacrolimus-induced acute esophageal necrosis without preceding hemodynamic instability in a liver transplant recipient, which resolved with discontinuation of tacrolimus and transition to cyclosporin.
- 1 July 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (7) , e01772
Open AccessTacrolimus-Induced Acute Esophageal Necrosis Postorthotopic Liver Transplantation
Acute esophageal necrosis, or “black esophagus,” is a rare but severe condition characterized by circumferential black necrotized esophageal mucosa with an abrupt transition at the gastroesophageal junction. The “two-hit” hypothesis suggests that an initial ischemic insult predisposes the esophageal mucosa to further injury from luminal acid exposure or medications. We present the first documented case of tacrolimus-induced acute esophageal necrosis without preceding hemodynamic instability in a liver transplant recipient, which resolved with discontinuation of tacrolimus and transition to cyclosporin.